![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinovac Says COVID-19 Vaccine Generated Immune Response
Sinovac Says COVID-19 Vaccine Generated Immune Response
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
Sinovac’s COVID-19 vaccine candidate induced an immune response, according to preliminary data from its phase 1/2 trial.
The Chinese drugmaker said the phase 2 portion of the trial showed the vaccine, called CoronaVac, induced neutralizing antibodies in 90 percent of participants 14 days after vaccination.
Sinovac said it will advance the vaccine to a phase 3 study “in the near future.”
Upcoming Events
-
21Oct